Funding Details
- Awarder
- Inbox
- Date Award
- May 18, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Rocketvax has signed a letter of intent with the U.S. National Institutes of Health (NIH) for a clinical trial as part of the Project NextGen initiative.
- Organizations Involved
- Emergent BioSolutions, U.S. National Institutes of Health
- Company Description
- Rocketvax Ltd is focused on developing next-generation vaccines using proprietary technology, including a live-attenuated nasal spray SARS-CoV-2 vaccine that has shown superior efficacy compared to mRNA COVID-19 vaccines in animal studies.
- Market
- Infectious diseases, cancer, and autoimmune disorders
- Location
-
United States
Links